However, due to the limited number of included studies, it is unclear whether there are differences in the correlation between irCAEs and survival across different tumours, between different types of irCAEs and survival, or between irCAEs and survival in patients treated with different PD-1/PD-L1 checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.